Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab — How These HER2 Drugs Differ

The comparison depends on your situation, not the drugs in isolation. In HER2-positive metastatic breast cancer after prior trastuzumab-based treatment, NCCN, ASCO and ESMO now place T-DXd as the preferred option over T-DM1 in that setting. In the adjuvant setting after residual disease following neoadjuvant chemotherapy, T-DM1 remains the standard recommendation — T-DXd is not the guideline choice there. The same drug can be exactly right in one situation and the wrong choice in another. Ask your oncologist which setting describes you.

HER2-low means your tumour has a small but detectable amount of HER2 protein — IHC 1+ or IHC 2+/ISH−. Until recently, this group was classified with HER2-negative disease and had no access to HER2-targeted drugs. T-DXd changed that. If your pathology report shows either of these results, ask your oncologist whether HER2-low status is now relevant to your options, particularly if you have metastatic hormone-receptor-positive disease that has progressed on prior treatment.

This transition appears in the pathways NCCN and ESMO describe for HER2-positive metastatic breast cancer. If T-DM1 has not achieved an adequate response or disease has progressed on it, T-DXd is among the options your oncologist may consider, depending on your lung function, overall fitness, and prior treatments. It is worth asking your team directly — the timing and sequence of the switch is something they can map against your specific situation.

T-DXd has shown intracranial activity in clinical data that ASCO and ESMO have incorporated into their guidance on HER2-positive breast cancer with brain involvement. T-DM1 and plain trastuzumab have limited ability to cross the blood-brain barrier. This does not automatically make T-DXd the right choice if you have brain metastases — the decision also depends on whether lesions are stable or active, their number and size, and what other options you have. Raise brain disease as a specific question at your next appointment rather than assuming the answer.

The difference is the payload. T-DXd carries a topoisomerase I inhibitor that is slightly membrane-permeable, meaning it can diffuse from cancer cells into surrounding tissue — including healthy lung tissue. This bystander effect is also what extends T-DXd's activity to HER2-low tumours. T-DM1's microtubule-disrupting payload does not have this property and stays within targeted cells. The lung risk with T-DXd is manageable with monitoring, but it is the reason any new respiratory symptom during treatment needs same-day reporting, not a wait-and-see approach.

HER2-targeted treatments including ADCs are administered as day-care infusions at CION centres across Telangana and Andhra Pradesh — you do not need to be admitted overnight. Your oncologist will confirm which drug applies based on your HER2 result and treatment sequence, arrange baseline assessments including lung and cardiac function, and schedule infusions accordingly. CION does not provide CAR-T or cell therapy; if that is relevant to your situation, you would be referred to a centre that offers it.